BMD and Fracture Benefit of Bisphosphonates
The effectiveness of these agents has been well documented. Alendronate and risedronate increase BMD and have demonstrated vertebral and nonvertebral antifracture efficacy, including reduction of the risk of hip fracture. ^32,35-37 They produce a relatively rapid antifracture effect against vertebral and hip fractures, maintain bone quality and have long-term antifracture benefit.